Acuris Risk Intelligence and FinScan® Announce Global Strategic Partnership
Acuris Risk Intelligence, an independent provider of data intelligence for Anti-Money Laundering (AML), Anti-Corruption and Cyber Security; and FinScan, a global leader in AML compliance solutions, have joined forces to deliver an integrated platform for seamless and efficient watch list screening and customer due diligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005681/en/
FinScan provides advanced sanctions, Politically Exposed Persons (PEP) and adverse media screening solutions for organisations worldwide. Its intelligent matching technology drastically reduces false positives and the risk of missing true hits. By combining FinScan’s accuracy and scalability with Acuris Risk Intelligence’s specialised knowledge, the partnership enables clients to screen customers and vendors against any high-risk or sanction lists using the deployment method of their choice.
Joel Lange, managing director at Acuris Risk Intelligence commented on the new partnership: “This collaboration will allow organisations to improve due diligence workflow processes through FinScan’s automated screening platform. With due diligence in the spotlight now more than ever, effective and comprehensive technologies will be key to staying on top of changing regulations.”
To address the ever-increasing demands on compliance professionals, Acuris Risk Intelligence and FinScan bring a deeper understanding, better workflows and higher precision to customer due diligence operations. By integrating Acuris Risk Intelligence sanction, PEP, source of wealth and adverse media data into FinScan, the two provide an increased level of transparency to clients in determining whether or not they need to act on highly suspicious activity.
“Automation is essential to enable regulated entities to step up their due diligence procedures in determining their customers’ legitimacy”, said Craig Robertson, FinScan’s managing director of the UK, MEA and APAC. “Our new collaboration with Acuris Risk Intelligence provides an additional level of clarity to our clients’ due diligence processes.”
About Acuris Risk Intelligence:
Acuris Risk Intelligence was
established in 2004 as C6 and rose to become one of the top suppliers of
proprietary PEPs, sanctions and AML data for due diligence and
compliance. It was acquired by Acuris Group in 2015. Today, Acuris Risk
Intelligence combines a world-class dataset – that now includes fraud
and cyber security content – with expert human analysts and
state-of-the-art technology to help organisations manage the risk in
business relationships effectively. Clients access our intelligence via
a SaaS platform, or via API and feed technology so risk protection is
built in to the way they operate. Our focus areas include third-party
risk, anti-money laundering and the proactive detection of cyber
security risk. For more information, please visit us at acurisriskintelligence.com
or call us on +44 (0) 203 742 1200.
About FinScan
FinScan is a leading global provider of
advanced anti-money laundering (AML) solutions. As the compliance brand
of Innovative Systems, a worldwide leader in data management and risk
management solutions, FinScan uniquely brings more than 50 years of
expertise in the development of data quality, data matching and linking
and name screening technologies. Our unparalleled risk and compliance
screening accuracy helps minimise false positives while reducing the
risk of missing true hits. FinScan’s comprehensive offerings include
sanctions and PEP screening, beneficial owner due diligence, transaction
screening and monitoring and ID validation capabilities. FinScan can be
deployed via on-premise, SaaS, or via web services to meet our clients’
data security, data privacy, or efficiency requirements. www.finscan.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005681/en/
Contact information
Brooke Petersen
Head of Marketing and Customer Success
Helping
businesses worldwide manage risk
A: 10 Queen Street Place, London,
EC4R 1BE
T: +44 (0) 203 741 1198
M: +44 (0) 771 761 8893
E:
Brooke.Petersen@acuris.com
W:
www.AcurisRiskIntelligence.com
Karin O’Sullivan
Vice President, Marketing Communications
+1
(412) 937-7678
kosullivan@innovativesystems.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reintroducing Global Blue to Retailers and Shoppers Worldwide19.3.2024 15:19:00 EET | Press release
Taking shopping further through the power of experience Over 40 years ago, Global Blue pioneered the concept of Tax Free Shopping, changing the retail landscape and empowering international shoppers worldwide. Since then, its journey has evolved, now encompassing three families of solutions: Tax Free Shopping, Payments, and Post-Purchase Solutions. Within these industries, Global Blue consistently leverages its integrated software and data to bring value at every step of the journey and take shopping further. Driven by this commitment, Global Blue teams create engaging experiences that foster connections between consumers and brands while simplifying processes, to ensure every customer journey is seamless and intuitive. Through these efforts, Global Blue enables its clients to seize business opportunities, enhance customer loyalty, boost sales, and optimize operations and costs. “At Global Blue, we firmly believe that improving the shopping journey drives performance. This renewed focu
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation19.3.2024 15:00:00 EET | Press release
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the healthcare regulatory body of the United Kingdom (UK), granted Innovation Passport designation to the Company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK. Maria Escolar, M.D., Forge’s Chief Medical Officer, will discuss the significance of achieving this regulatory designation and present a poster on updated data from REKLAIM, an early phase clinical trial for FBX-101, during the Advanced Therapies 2024 conference being held in London, March 19-20, 2024. “Considering the rapid progression of
SWISSto12 Continues Expansion, Growing Team by 25% and Adding New Production Space19.3.2024 15:00:00 EET | Press release
SWISSto12, one of Europe’s fastest growing aerospace companies and a leading satellite and Radio Frequency product manufacturer, announces its continued global expansion. The company has secured additional production space at its headquarters in Switzerland, increasing the size of its existing site to 5,700m2. In addition, SWISSto12 has welcomed several new Satcom engineering experts to its growing team, which has increased by 25% since the start of 2024 to over 125 employees working across its facilities in Switzerland, Europe and the USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318493042/en/ HummingSat I-8 Inmarsat (Photo: Business Wire) SWISSto12 was recently named as one of the world’s “10 Hottest Satellite Companies.” This industry recognition follows the company’s announcement in Q4 2023 of securing over €200 million in customer orders for Radio Frequency subsystems and HummingSat satellites, including from l
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up19.3.2024 15:00:00 EET | Press release
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/ The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire) The publication is available here: https://www.sciencedirect.com/science/article/pii/S1094715924000552 The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success
AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 14:04:00 EET | Press release
AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom